Close Menu


The suit, filed by the UI Research Foundation, claims that Abbott has infringed one or more claims of the patents by manufacturing its billion-dollar blockbuster monoclonal antibody Humira, which is used to treat a variety of autoimmune diseases.

A California bill, sponsored by 23andMe, would essentially exempt certain personal genomics firms from having to meet CLIA standards, but would create new requirements for the nascent industry. Privacy groups and members of the personalized medicine community are concerned that the bill doesn't go far enough to protect consumers' genetic information or ensure the accuracy of these tests.

Navigenics' $2,500 Health Compass service, launched in 2007 to screen for the genetic risk of 23 conditions, now screens for 28 conditions. The company also added new SNPs to its service to improve risk screening for various conditions it already tested for, such as Alzheimer's disease.

The company will offer its service for $48,000 through a physician, and will conduct the sequencing at its newly CLIA-certified laboratory in San Diego. Illumina has teamed up with 23andMe, Navigenics, Decode Genetics, and Knome to interpret the data.

In launching its personal genome service today here at the Consumer Genetics conference, Illumina announced that it will charge $48,000 to analyze patients DNA by whole-genome sequencing. Customers can then sign up with DTC genomic testing partners to get more information on how their genes tie in with medical outcomes.

Unlike most DTC genomic-firms, which allow customers to order gene scans over the Internet and receive sample collection kits in the mail, Illumina’s service will require a prescription from their doctor or from a physician in its Personal Genome Network.

IP Update: Apr 30, 2009


USPTO Publishes One Patent, Seven Patent Applications Related to RNAi

Snippets: Apr 29, 2009


MDS Pharma Services, Compendia Bioscience, CombiMatrix, Decode Genetics

The Nasdaq Listing and Hearing Review Council called for a review of an April 22 determination of the Nasdaq Listing Qualifications Panel that it would have delisted Decode's shares on April 30.

Celera plans to use the SNPs to develop personalized risk tests for heart attack, stroke, and type 2 diabetes.


In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.